23.05.2017
- AstraZeneca has sold European rights for its Seloken/Seloken ZOK and Logimax cardiovascular drugs to Italy’s Recordati for $300 million. The medicines, which are used to treat...
03.09.2014
- A new experimental heart failure medication developed by Swiss drugmaker Novartis with the working name of LCZ696 is being widely regarded as having potential to significantly...
